Copyright
©The Author(s) 2017.
World J Gastroenterol. Dec 21, 2017; 23(47): 8355-8366
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8355
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8355
Figure 1 The selection of the study population and experimental design.
20 patients except for 25 patients to meet the exclusion criteria and decline to participate were finally analyzed.
- Citation: Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol 2017; 23(47): 8355-8366
- URL: https://www.wjgnet.com/1007-9327/full/v23/i47/8355.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i47.8355